60
Participants
Start Date
October 23, 2020
Primary Completion Date
June 3, 2027
Study Completion Date
June 3, 2027
Turoctocog alfa pegol (N8-GP)
Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
PeK - University Children's Hospital, Department of haematology, Ljubljana
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Vienna
"UMHAT Tsaritsa Yoanna-ISUL", Sofia
Kinderspital Hämatologie, Zürich, Zurich
A.O.U Città Salute Scienza Torino, Torino
Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain, Berlin
"Laiko General Hospital of Athens", Athens
North Estonia Medical Centre Foundation, Tallinn
Hospital Regional Universitario de Málaga, Málaga
Ospedale San Bortolo, Vicenza
Azienda Ospedaliera-Universitaria Parma, Parma
Tartu University Hospital Haematology Clinic, Tartu
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn
KBC Zagreb, Rebro, Hemofilija centar, Zagreb
FN Brno odd. hematologie, Brno
FN HK - IV. Interni hematologicka klinika, Hradec Králové
"Laiko General Hospital of Athens", Athens
Aghia Sophia Childrens' Hospital, Athens
MH Eü. Központ -Orszagos Haemophilia Kozpont, Budapest
"Hospital of LUHS Kauno Klinikos", Kaunas
Republican Panevezys Hospital, Public consultation clinic, Panevezys
Vilnius University hospital Santaros klinikos, Vilnius
Vilnius University hospital Santaros klinikos, Vilnius
Centro Hospitalar Lisboa Norte-HSM, Lisbon
ULS São João, E.P.E., Porto
Unilabs Slovensko, s. r. o., Košice
Lead Sponsor
Novo Nordisk A/S
INDUSTRY